Pharmion Purchases Cabrellis, US Developer of Amrubicin

December 1, 2006
Oncology NEWS International, Oncology NEWS International Vol 15 No 12, Volume 15, Issue 12

Pharmion Corporation has acquired Cabrellis Pharmaceuticals and gained US and European rights to amrubicin, a third-generation synthetic anthracycline currently in phase II trials for small-cell lung cancer in North America and Europe.

BOULDER, Colorado—Pharmion Corporation has acquired Cabrellis Pharmaceuticals and gained US and European rights to amrubicin, a third-generation synthetic anthracycline currently in phase II trials for small-cell lung cancer in North America and Europe.

Related Content:

Lung Cancer